.

Coherus Biosciences | CHRS

Coherus Biosciences traded at $9.37 this Monday October 3rd, decreasing $0.24 or 2.50 percent since the previous trading session. Looking back, over the last four weeks, Coherus Biosciences lost 6.77 percent. Over the last 12 months, its price fell by 40.73 percent. Looking ahead, we forecast Coherus Biosciences to be priced at 9.32 by the end of this quarter and at 8.51 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
LG Chem 550,000.00 14,000.00 2.61% -23.29%
Fujifilm 6,936.00 125.00 1.84% -21.71%
AbbVie 138.32 4.11 3.06% 27.21%
Acadia Pharmaceuticals 17.04 0.68 4.16% 1.49%
Aerie Pharmaceuticals 15.10 -0.03 -0.20% 33.16%
Akebia Therapeutics 0.31 -0.002 -0.66% -88.78%
ALKERMES 22.95 0.62 2.78% -24.80%
Alnylam Pharmaceuticals 196.79 -3.37 -1.68% 0.91%
Amgen 230.44 5.04 2.24% 8.99%
Amarin 1.12 0.03 2.75% -77.56%
Baxter International 55.62 1.76 3.27% -30.84%
Biogen 264.30 -2.70 -1.01% -5.04%
Bluebird Bio 6.13 -0.20 -3.16% -66.76%
BioMarin Pharmaceutical 86.70 1.93 2.28% 14.26%
Bristol-Myers Squibb 70.53 -0.56 -0.79% 19.68%
Coherus Biosciences 9.37 -0.24 -2.50% -40.73%
Endo International 0.09 -0.01 -5.27% -97.34%
Gilead Sciences 62.32 0.63 1.02% -7.76%
Horizon Pharma 64.26 2.37 3.83% -42.40%
Ironwood Pharmaceuticals 10.37 0.01 0.10% -21.20%
Jazz Pharmaceuticals 135.45 2.16 1.62% 6.48%
Eli Lilly 321.55 -1.80 -0.56% 43.01%
Merck & Co 87.55 1.43 1.66% 5.36%
Myriad Genetics 19.58 0.50 2.62% -36.65%
Pacira 55.07 1.88 3.53% 11.37%
Pfizer 44.14 0.38 0.87% 4.05%
Perrigo 36.53 0.87 2.44% -24.09%
PTC Therapeutics 50.68 0.48 0.96% 37.53%
Regeneron Pharmaceuticals 734.93 46.26 6.72% 32.32%
Revance Therapeutics 28.23 1.23 4.56% 4.56%
Sarepta Therapeutics 109.94 -0.60 -0.54% 16.14%
Teva Pharmaceutical Industries Ltd 2,946.00 76.00 2.65% -6.74%
Vertex Pharmaceuticals 297.43 7.89 2.73% 68.03%
Xencor 25.83 -0.15 -0.58% -27.28%
Zoetis 151.35 3.06 2.06% -21.86%

Indexes Price Day Year
USND 10815 239.82 2.27% -24.13%
US400 2268 64.32 2.92% -14.97%

Coherus Biosciences
Coherus BioSciences, Inc. is a commercial stage biotherapeutics company. The Company is focused on the biosimilar and immuno-oncology market primarily in the United States. The Company’s pipeline includes the four categories product candidates, Oncology pipeline, Immunology pipeline, Ophthalmology pipeline and Small Molecule pipeline. Oncology pipeline includes Toripalimab, an anti-PD-1 antibody; UDENYCA (pegfilgrastim-cbqv); CHS-305, a bevacizumab (Avastin) biosimilar. Immunology pipeline includes CHS-1420, an anti-TNF product candidate, as an adalimumab (Humira) biosimilar. Ophthalmology pipeline includes CHS-201, a ranibizumab (Lucentis) biosimilar. CHS-201, a ranibizumab (Lucentis) biosimilar. Small Molecule pipeline includes CHS-131, an oral, small-molecule drug candidate. CHS-131 is a once-daily oral drug candidate for non-alcoholic steatohepatitis (NASH) and other metabolic conditions.